Predictors and time to recovery from COVID-19 among patients attended at the treatment centers in Ekiti State, South West, Nigeria

Oluwabunmi Samuel Ibitoye, Yusuff Akinkunmi Olasunkanmi, Tubosun Alex Olowolafe, Aderemi Temitayo Olabode, Mobolaji Modinat Salawu, Rotimi Felix Afolabi

Corresponding author: Mobolaji Modinat Salawu, Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria. sannibolaji@yahoo.com

Received: 15 Feb 2022 - Accepted: 01 Apr 2022 - Published: 09 May 2022

Keywords: COVID-19, predictor, time to recovery, Nigeria

Copyright: Oluwabunmi Samuel Ibitoye et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Oluwabunmi Samuel Ibitoye et al. Predictors and time to recovery from COVID-19 among patients attended at the treatment centers in Ekiti State, South West, Nigeria. Pan African Medical Journal. 2022;42(18). 10.11604/pamj.2022.42.18.33791

Available online at: https://www.panafrican-med-journal.com/content/article/42/18/full

Predictors and time to recovery from COVID-19 among patients attended at the treatment centers in Ekiti State, South West, Nigeria

Oluwabunmi Samuel Ibitoye, Yusuff Akinkunmi Olasunkanmi, Tubosun Alex Olowolafe, Aderemi Temitayo Olabode, Mobolaji Modinat Salawu, Rotimi Felix Afolabi

1Ekiti State Hospitals Management Board, Ekiti, Nigeria, 2Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria, 3Health Promotion and Education, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria

Corresponding author
Mobolaji Modinat Salawu, Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria
Abstract

Introduction: time to clinical recovery from COVID-19 infection and associated factors has not been explored in Nigeria. This study was conducted to assess the predictors and time to recovery from COVID-19 among patients attended to at the treatment centers in Ekiti State, South West. Methods: a facility-based retrospective cohort study was conducted between March 2020 to October 2021. Laboratory confirmed COVID-19 positive test result of 586 patients receiving treatment at the treatment centres in Ekiti were included. Data were extracted from COVID-19 intake forms and medical records of patients. Data were analysed using descriptive statistics and survival analysis methods including Cox proportional hazards regression model. Level of significance was set at 5%. Results: the mean age of the patients was 43.46 (SD 0.74) years. Forty-seven percent (47%) of the patients were aged 25-44 years, fifty-one percent (51%) were males. The median recovery time of COVID-19 patients was 21 days (IQR: 14-23). Being a male-patient (95% CI 20.46-21.54), older age (95% CI 20.14-21.86), not admitted in the hospital (95% CI 22.74-23.26), and associated multiple co-morbidities (95% CI 17.65-28.35) were associated with delayed recovery time. Predictors of recovery time of patients from COVID-19 infection were admission status (aHR: 0.71, 95%CI 0.56-0.88; p=0.002) and symptoms on admission (aHR: 0.81, 95%CI 0.66-0.99; p=0.020). Conclusion: patients with comorbidities, older and those not admitted were more likely to have a delayed clinical recovery from COVID-19. Knowledge of the predictors might help health professionals in risk stratification and better management of patients with COVID-19.

Introduction

The World Health Organisation (WHO) declared COVID-19 outbreak as a public health emergency of international concern and a pandemic on 30th January and 11th March 2020 respectively [1]. Globally, more than 243 million people had been infected with COVID-19 and above five million deaths had been reported as of November 30, 2021 [2]. In Africa, the number of confirmed cases has continued to rise with over six million cumulative cases, representing 3% of global cases [3]. This has continued to stretch the health system as a result of pre-existing epidemics that are of critical concern [4].

In Nigeria, the index case of COVID-19 was reported on the 27th February, 2020. Currently, COVID-19 infection has been reported in all the thirty-six states of the country including Federal Capital Territory. Of 3,298,966 samples tested, there were 211,921 confirmed cases, 203,248 survivors and 2,896 deaths as at November 1, 2021 [5]. The epicenter of the pandemic remains Lagos State with over 77,000 and least in Ekiti State with over 1,700 confirmed cases, both in the South West of the country [5].

COVID-19 continues to cause unprecedented morbidity and mortality, with a wide range of case-fatality rate across countries of the world including Nigeria. Clinical recovery from COVID-19 illness has been linked to demographics such as age, comorbidity, existing health care system and several unidentified factors [6,7]. The WHO report documented that the average recovery time from COVID-19 ranges from one to two weeks and three to six weeks for patients with mild and severe infections respectively [8]. A retrospective cohort study in Ethiopia among COVID-19 patients reported a median time to recovery of 18 days [9]. Another Ethiopian study among COVID-19 patients reported a range of 9 to 17 days with median recovery time of 13 days [6]. The average recovery time among COVID-19 patients in Indian states ranged from 5 to 36 days [10].

Nigeria Center for Disease Control (NCDC) reported that more than 95 percent of persons that tested positive for COVID-19 recovered from the disease [5]. However, the predictor and time to recovery from COVID-19 is yet to be documented in Nigeria. Knowledge of the predictors might help health professionals in risk stratification and better
management of patients with COVID-19. This study was conducted to document the predictor(s) and time to recovery from COVID-19 among patients attended to at the treatment centers in Ekiti State, South West, Nigeria.

Methods

Study design and area: a facility-based retrospective cohort study on recovery time from COVID-19 infection and its determinants among patients attended to from March 15, 2020 to October 21, 2021 to the treatment centres in Ekiti State, Nigeria. The secondary data utilised for this study was extracted from the registration logbook, COVID-19 intake forms and medical records of patients containing information on socio-demographic (such as age, sex among others), disease and past medical history, admission status clinical and laboratory characteristics of the patients. Ekiti state is located in the South-West region of Nigeria. As at 2006, the state had a total population of 2,398,957 [11]. In Ekiti state, the first case of COVID-19 was confirmed on the March 15, 2020. As at October 2021, Ekiti state had 1777 cases on record, with about 1726 patients who had recovered [5].

Study population, sample size and sampling technique: this comprised of all patients who tested positive to COVID-19 using the antigen based rapid diagnostic test and reverse transcriptase polymerase chain reaction (RT-PCR), who were receiving treatment at any of the treatment centres in Ekiti State. A total of 597 patients case records were available within the study period, but only 586 had complete baseline information with outcome variable and were therefore included in the analysis. All COVID-19 patients attended to at the treatment centers from March 15, 2020 to October 21, 2021 and fulfilled inclusion criteria were included in this study. A total of 586 COVID-19 patients' case record date was analysed.

Study variables: the outcome variable for this study was time to recovery of patients from COVID-19 disease. The recovery time was estimated as number of days elapsed between confirmed date of positive test results and the subsequent confirmed date of negative test results among patients attended to at the COVID-19 treatment centres. In this study, patients who did not recover from the COVID-19 infection as at October 21, 2021 or those who died during the period of the study were right-censored. The explanatory variables considered for this study were patients’ socio-demographic and health characteristics which were: age (<24, 25-44, 45-64, ≥65 years), sex (male and female), admission status (admitted - for isolation and severity of illness; not admitted i.e. patients being managed from home as a result of mild symptoms, lack of space), symptoms on admission, oxygen therapy, presence of and the comorbidity conditions and recovery status (discharged after healthy certification, discharge against medical advice, death, referred to another centre). Recovery status was exclusively analysed based on patients that were discharged after health certification. Recall bias was envisaged in recollecting information regarding comorbid conditions. However, data relating to past medical history were extracted from available pre-existing patients’ records.

Data analysis: survival analysis techniques were used for this analysis. The “survival time” for patients who had recovered was the recovery time from confirmed cases of COVID-19 disease. Patients without confirmed negative test results at the end of the study were censored from the study. This was coded as zero (0); otherwise, it was coded one (1). The Kaplan-Meier survival method was used to describe the patient’s time to recovery from COVID-19 disease. The log-rank test was used to explore the association between COVID-19 recovery time and each of the independent variables. All significant variables (p<0.05) due to the log-rank test were thereafter included in the semi-parametric Cox proportional hazard
regression to explore the predictors of COVID-19 recovery time. The adjusted hazard ratios (aHR) and their respective 95% confidence intervals are reported. All analyses were conducted at a 5% level of significance, using STATA 14.

Ethical considerations: ethical clearance was obtained from the Research and Ethics Committee for Planning and Statistics Department of Hospitals Management, Ekiti State (HMB/AD.567T/12). Permission was also obtained from the hospital administration for conduct of the research.

Results

Socio-demographic characteristics of patients: The mean age of the patient was 43.46 (0.74) years. Of 586 participants, two hundred and seventy-nine of them (47.6%) were between 25-44 years while one hundred and fifty-nine (27.1%) were aged 45 to 64 years. Two hundred and ninety-nine (51%) of the patients were males. Four hundred and sixty-eight (79.9%) of the patients were admitted to the treatment centres, and three hundred and two of them (47.6%) were between 24 years, 25-44 years, 45-64 years and ≥ 65 years was 16 days (IQR: 14-23), 21 days (IQR: 14-23), 22 days (IQR: 15-23) and 22 days (IQR: 14-24) respectively (P<0.05). The median recovery time for patients that were admitted was 18 days (IQR: 14-23) while for patients that were not admitted was 23 days (IQR: 22-23) at p<0.05. The median recovery time of patients without any form of co-morbidity condition was 21 days (IQR: 14-23) while the median recovery time of patients with co-morbidity condition was 22 days (IQR: 17-24) p<0.05. The median recovery time of patients with hypertension, diabetes and other forms of diseases (pneumonia, chronic ulcer, uterine fibroid, cancer, TB), diabetes and hypertension were 21 days (IQR: 17-23), 23 days (IQR: 19-53), and 22 days (IQR: 17-26) respectively p<0.05 (Table 3).

Treatment outcome among patients: Seven (1.2%) of the patients were still on treatment at the time of data collection, 30 (5.1%) of the patients died at the point of receiving treatment. At the end of the follow-up, 539 (92%) of the patients in the cohort recovered from the COVID-19 infection. Table 2 shows the chance of recovery of patients from the COVID-19 virus at different time points (days) after being attended to at the treatment centers. The probability of recovery from the COVID-19 virus in 10 days was 0.0814, with about 8% of the patients recovering from the virus in 10 days. Forty six percent of the patients recovered in 20 days, with most (90%) of the patients recovering from the virus at 25 days.

Recovery rate and median recovery time from COVID-19: Of the 586 patients surveyed, 539 of them recovered within median recovery time of 21 (IQR: 14-23) days. The overall incidence rate of recovery was 4.70 per 100 (95% CI: 41.89-50.15) person-day observation. The overall median recovery time of COVID-19 patients was 21 days (IQR: 14-23) days presented in Figure 1A. Also, in Table 3, it can be observed that the median recovery time for male patients is 21 days (IQR: 15-23) as compared to the median recovery time for females which is 20 days (IQR: 14-23) at P<0.05. The median recovery time for patients aged < 24 year, 25-44 years, 45-64 years and ≥ 65 years was 16 days (IQR: 14-23), 21 days (IQR: 14-23), 22 days (IQR: 15-23) and 22 days (IQR: 14-24) respectively (P<0.05). The median recovery time of patients that were admitted was 18 days (IQR: 14-23) while for patients that were not admitted was 23 days (IQR: 22-23) at p<0.05. The median recovery time of patients without any form of co-morbidity condition was 21 days (IQR: 14-23) while the median recovery time of patients with co-morbidity condition was 22 days (IQR: 17-24) p<0.05. The median recovery time of patients with hypertension, diabetes and other forms of diseases (pneumonia, chronic ulcer, uterine fibroid, cancer, TB), diabetes and hypertension were 21 days (IQR: 17-23), 23 days (IQR: 19-53), and 22 days (IQR: 17-26) respectively p<0.05 (Table 3).

The Kaplan-Meier survival curve representing the recovery time of COVID-19 with respect to patients’ health characteristics as covariates (admission status, symptoms on admission, presence of comorbidity, comorbidity condition) is constructed which are presented in Figure 1 (B-F). Kaplan-Meier survival curves were constructed to estimate the survival time based on different covariates to see the existence of differences in the recovery rate among categories of individual covariates. From the Kaplan Meier survival curve of individual covariates, there was no difference in the recovery rate of patients that received oxygen therapy and patients that didn’t receive oxygen therapy. However, there were different recovery rates among other covariates such as sex, age, admission status, symptoms on admission, comorbidities.
status, symptoms on admission, presence of co-morbidity and co-morbidity condition (Figure 1 (B-F)). To show the significant difference in the covariates, a log-rank test was computed at a 5% significance level. There was a significant difference in survival status of patients to their sex, age, admission status, symptoms on admission, presence of co-morbidity and co-morbidity condition.

Predictor of recovery time from COVID-19: patients with symptoms on admission aHR = 0.81, 95% CI 0.66-0.99; p =0.02 were 0.81 times less likely to recover from the COVID-19 virus compared to patients without symptoms on admission. Patients that were not admitted aHR = 0.71, 95% CI 0.57-0.89; p=0.002 were 0.71 times less likely to recover compared to those that were admitted. Patients with hypertension only aHR = 1.56, 95% CI 0.63-3.86; p=0.330 had 1.56 times higher chance of recovery time compared to patients with diabetes, hypertension with diabetes and other co-morbidity (pneumonia, chronic ulcer, tuberculosis) (Table 4).

Discussion

The COVID-19 pandemic is a public health emergency with an unprecedented scale. With the changing dynamics of the epidemiology of COVID-19, an understanding of the survival time as well as associated factors is important. This study assessed the time to recovery from COVID-19 and its predictors among adults in Ekiti State, South western, Nigeria. The study found out that clinical recovery from COVID-19 infection was delayed in patients who were older, had comorbidities, and those not admitted in the hospital. In this study, more than two-fifth of the patients recovered from the virus at 15 days of receiving treatment. A study by [12], conducted in India reported similar findings of 29% of patients recovering at 15th day of the treatment [13]. However, a study by Liu et al. in Australia reported that an estimate of 80% of the patients recovered after one month of treatment [14]. This difference in recovery rate maybe as a result of difference in weather condition, as reported by Mehmet in a research in Turkey that there is a negative correlation between temperature and transmission of COVID-19, which can also have an effect on patients’ recovery especially if the patient is asymptomatic [15].

Our study findings showed the median recovery time from COVID-19 virus was 21 days. This is similar to a study by Bi et al. and Zhour et al. in Shenzhen and Wuhan in China which reported a recovery time of 21 days from COVID-19 [16,17]. Wang et al. in another study in Wuhan reported an estimated median recovery time of 21 days which is similar to our study finding [18]. However, some other studies by Voinsky in Israel and Hu et al. in Shanghai documented lower median recovery time of 13.2 days and 11 days from COVID-19 respectively [19,20]. Furthermore, Abdella in a study carried out in Ethiopia reported an estimated median recovery time of 19 days from COVID-19 [21]. This time to viral load clearance is also similar to our study findings. The disparity in median recovery time in these studies could be due to study site, study sample size, changes in the country’s socio-economic situation as a result of the pandemic, disease severity, type of specimen tested, care and treatment given.

In this study, we found that female patients will most likely recover before the male patients because the predictive recovery time was lesser for female patients. This finding was similar to other studies conducted in Israeli, Wuhan and Ethiopia [16-21]. However in another study by Liu et al. in Australia, there was no significant association between sex of the study participant and time to recovery [14]. This can be explained in terms of sex-related differences that exist between males and females; as the latter are believed to have stronger immune system compared to males, and higher level of cortisol and oestrogen which are beneficial [22,23].

Our study further revealed that the presence of comorbidity is an independent risk factor that can delay the recovery of patients from COVID-19. This finding was supported by different studies which identified the presence of comorbidity in COVID-19
patients led to delay in recovery [20,24,25]. Although, there were other studies that reported no significant association between the presence of comorbidity and time to recovery from COVID-19 [26,27]. The observed difference could be as a result of varying treatment guidelines for the management of these comorbidities in the different study site. In addition, there is the possibility of variation in patients’ response to treatment which may have an effect on recovery time form COVID-19.

In this study, we found a significant association between age and time to recover from COVID-19, which showed that the median recovery time for patients below the age 24 years was 16 days while older patients aged 45 years and above had median recovery time of 22 days. A few other studies conducted in China reported similar findings [20,26]. However, Abdella in a study on time to recover and its predictors among adults hospitalized in Ethiopia found no association between age and viral clearance [21]. In addition, Qi et al. in a study on factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, Chins reported no significant difference between age duration of viral shedding [28]. Natural ageing process is characterized by a decline in physiological functions and weakened immune system. It is sometimes associated with comorbid disorders which also predispose the aged to elongate recovery time and hence could result in poor clinical outcomes in older adults with COVID-19 [29].

The predictors time to clinical recovery of patients with COVID-19 infection within the median time of recovery were admission status, symptoms on admission and presence of comorbidity. COVID-19 patients that were not admitted were less likely to recover early as compared to those that were admitted. Patients with symptoms on admission were also less likely to recover quickly from the COVID-19 compared to patients without symptoms on admission. Patients with hypertension only has little higher chance of recovery within the median time of recovery compared to patients with diabetes, hypertension with diabetes and other co-morbidity such as pneumonia, chronic ulcer, tuberculosis. Research has documented that COVID-19 complications is severe among people with underlying health conditions and treatment outcomes are always unfavourable [30-32]. Leulseged et al. reported that presence or absence of co-morbid symptoms among COVID-19 patients was a significant factor that influenced recovery days [33]. This is also similar to a study by Tolossa which reported that symptoms and comorbidity were key factors that determine COVID-19 treatment recovery time [34]. Osibogun in another study in Lagos, Nigeria found out that comorbidity and the level of its severity were the cause of patients’ deaths and recovery [35].

This is the first study to document predictors and time to recover from COVID-19 infection in Nigeria. However, some limitations are noted. Firstly, this was a retrospective study which limited further exploratory analysis because some other useful information as regards patients’ socio-demographic information, clinical features/state and other laboratory findings might not have been captured. Secondly, recall bias was envisaged in this study as patients may find it difficult to recall information in the past as regards their co-morbid conditions that could be related to COVID-19 viral clearance. However, we were able to assess some data relating to past medical history from available pre-existing patients´ records.

**Conclusion**

This retrospective cohort study showed that the recovery time from COVID-19 infection is long and is particularly longer in patients with other co-morbidities, older adults and patients that were not on admission. Therefore, aged COVID-19 patients, and persons with one or more co-morbidities should be given priority for COVID-19 preventive interventions. In addition, these findings will assist the clinician to triage and administer appropriate and timely treatment to COVID-19 patients which gives a favourable clinical outcome.
What is known about this topic
- Epidemiology of COVID-19 infection has been explained in many published literatures;
- Prevalence and clinical symptoms associated with COVID-19 infection has been established.

What this study adds
- This study has added scientific evidence on time to clinical recovery of patients from COVID-19 infection. It has also demonstrated significant predictors of patients’ clinical recovery from COVID-19 infection.

Competing interests
The authors declare no competing interests.

Authors' contributions
Conception and study design: OSI, YAO and MMS. Data collection: OSI and YAO. Data analysis and interpretation: YAO, MMS, and RFA. Manuscript drafting: YAO, TAO, ATO and MMS. Manuscript revision: YAO, MMS, and RFA. Guarantor of the study: MMS. All the authors have read and agreed to the final manuscript.

Acknowledgments
We acknowledge the nurses, doctors and medical record officers at the treatment centres in Ekiti State, Nigeria for their assistance in compilation of the study data. We also thank staff of the Research and Statistics unit of State Ministry of Health, Ekiti State, Nigeria.

Tables and figure

Table 1: socio-demographic and clinical characteristics of COVID-19 cases attended at the treatment centres in Ekiti State
Table 2: probability of patients’ clinical recovery from COVID-19 at different time point
Table 3: median duration of recovery from COVID-19 with respect to the covariates for patients attended at the treatment centres in Ekiti State
Table 4: multivariable Cox regression analysis of time to recovery and its predictors among patients attended at the treatment centres in Ekiti State
Figure 1: Kaplan-Meier recovery curve of COVID-19 patient with respect to the covariates

References
1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Accessed September 15, 2021.
2. World Health Organization. COVID-19 weekly epidemiological update, edition 58, 21 September 2021. Accessed September 21, 2021.
3. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nat Rev Immunol. Nat Rev Immunol. 2021 Aug;21(8): 469-470. PubMed | Google Scholar
4. Global Fund. The global fund results report 2021. September 8, 2021. Accessed September 15, 2021.
5. NCDC. COVID-19 situation report 2021. Weekly epidemiologic report 57. Epi week 45: 8th-14th November 2021. Accessed November 21, 2021.
6. Kaso AW, Hareru HE, Kaso T, Agero G. Time to recovery from COVID-19 and its associated factors among patients hospitalized to the treatment center in South Central Ethiopia. Environmental Challenges. 2022;6: 100428. Google Scholar
7. Bhapkar HR, Mahalle PN, Dey N, Santosh KC. Revisited COVID-19 mortality and recovery rates: are we missing recovery time period? J Med Syst. 2020 Oct 25;44(12): 202. PubMed | Google Scholar
8. World Health Organization. Report of WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). Accessed October 10, 2021
9. Tolossa T, Wakuma B, Seyoum Gebre D, Merdassa Atomssa E, Getachew M, Fetensa G et al. Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study. PLoS ONE. 2021 Jun 10;16(6): e0252389. PubMed | Google Scholar

10. George N, Tyagi NK, Prasad JB. COVID-19 pandemic and its average recovery time in Indian states. Clin Epidemiol Glob Heal. Jul-Sep 2021;11: 100740. PubMed | Google Scholar

11. National Population Commission. Federal Republic of Nigeria official gazette. 2009. Accessed October 22, 2021.

12. Sharma P, Chen V, Fung CM, Troost JP, Patel VN, Combs M et al. COVID-19 outcomes among solid organ transplant recipients: a case-control study. Transplantation. 2021;105(1): 128-137. PubMed | Google Scholar

13. Pratim M, Rahman T, Bora K, Borgohain C. Diabetes & metabolic syndrome: clinical research & reviews COVID-19 pandemic and its recovery time of patients in India: a pilot study. Diabetes Metab Syndr Clin Res Rev. 2020;14(5): 1205-1211. PubMed

14. Liu B, Jayasundara D, Pye V, Dobbins T, Dore GJ, Matthews G et al. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. Lancet Reg Health West Pac. 2021 Jul;12: 100193. PubMed | Google Scholar

15. Mehmet S. Science of the total environment impact of weather on COVID-19 pandemic in Turkey. August 1, 2020;728: 138810. Google Scholar

16. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8): 911-919. PubMed | Google Scholar

17. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229): 1054-1062. PubMed | Google Scholar

18. Wang K, Zhang X, Sun J, Ye J, Wang F, Hua J et al. Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019. Chest. 2020;158(5): 1876-1884. PubMed | Google Scholar

19. Irena Voinsky, Gabriele Baristaite DG. Effects of age and sex on recovery from COVID-19: analysis of 5769 Israeli patients. J Infect. 2020;81(2): e102-e103. PubMed | Google Scholar

20. Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci Total Environ. 2020 Aug 1;728: 138812. PubMed | Google Scholar

21. Abrahim SA, Tessema M, Defar A, Hussein A, Ejeta E, Demoz G et al. Time to recovery and its predictors among adults hospitalized with COVID-19: a prospective cohort study in Ethiopia. PLoS One. 2020 Dec 30;15(12): e0244269. PubMed | Google Scholar

22. Kamran I, Tasneem Z, Parveen T, Zaidi Y. Investigating the low modern contraceptive use in pakistan. Popul Counc Islam Pakistan. 2015.

23. Larsson CA, Gullberg B, Råstam L, Lindblad U. Salivary cortisol differs with age and sex and shows inverse associations with WHR in Swedish women: a cross-sectional study. BMC Endocr Disord. 2009 Jun 21;9: 16. PubMed | Google Scholar

24. Fu Y, Han P, Zhu R, Bai T, Yi J, Zhao X et al. Risk factors for viral RNA shedding in COVID-19 patients. Eur Respir J. 2020 Jul 2;56(1): 2001190. PubMed | Google Scholar
25. Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020;288(1): 128-138. PubMed | Google Scholar
26. Chen X, Zhu B, Hong W, Zeng J, He X, Chen J et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis. 2020;98: 252-260. PubMed | Google Scholar
27. Qi L, Yang Y, Jiang D, Tu C, Wan L, Chen X et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. Int J Infect Dis. 2020;96: 531-537. PubMed | Google Scholar
28. Qi H, Xiao S, Shi R, Ward MP, Chen Y, Tu W et al. COVID-19 transmission in Mainland China is associated with temperature and humidity: a time-series analysis. Sci Total Environ. 2020;728: 138778. PubMed | Google Scholar
29. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. Intervirology. 2020 Dec 9;1-12. PubMed | Google Scholar
30. Jakhmola S, Indari O, Baral B, Kashyap D, Varshney N, Das A et al. Comorbidity assessment is essential during COVID-19 treatment. Front Physiol. 2020 Aug 4;11: 984. PubMed | Google Scholar
31. Klein F. Risikofaktor Komorbiditäten bei COVID-19- Erkrankung. Pneumologie. 2020;74(10): 640. Google Scholar
32. Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55(6): 1069-1076. PubMed | Google Scholar
33. Leulseged TW, Maru EH, Hassen IS, Zewde W. Predictors of death in severe COVID-19 patients at millennium COVID-19 care center in ethiopia: a case-control study. Pan Afr Med J. 2021 Apr 12;38: 351. PubMed | Google Scholar
34. Tolossa T, Wakuma B, Seyoum Gebre D, Merdassa Atomssa E, Getachew M, Fetensa G et al. Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: survival analysis of retrospective cohort study. Plos one. 2021;8: 1-12. Google Scholar
35. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One. 2021 Mar 15;16(3): e0248281. PubMed | Google Scholar
**Table 1:** socio-demographic and clinical characteristics of COVID-19 cases attended at the treatment centres in Ekiti State

| Variable                           | N (586) | %    |
|------------------------------------|---------|------|
| **Age (years)**                    |         |      |
| Mean±SD                            | 43.49±0.74 |      |
| <24                                | 63      | 10.8 |
| 25-44                              | 279     | 47.6 |
| 45-64                              | 159     | 27.1 |
| ≥65                                | 85      | 14.5 |
| **Sex**                            |         |      |
| Male                               | 299     | 51   |
| Female                             | 287     | 49   |
| **Admission status**               |         |      |
| Admitted                           | 468     | 79.9 |
| Not admitted                       | 118     | 20.1 |
| **Symptoms on admission**          |         |      |
| Absent                             | 284     | 48.5 |
| Present                            | 302     | 51.5 |
| **Oxygen therapy**                 |         |      |
| No                                 | 497     | 84.8 |
| Yes                                | 89      | 15.2 |
| **Presence of comorbidity**        |         |      |
| No                                 | 429     | 73.2 |
| Yes                                | 157     | 26.8 |
| **Comorbidity condition**          |         |      |
| No condition                       | 434     | 74.1 |
| Hypertension                       | 66      | 11.3 |
| Diabetes                           | 15      | 2.6  |
| Hypertension and diabetes          | 47      | 8    |
| *Others                            | 24      | 4.1  |
| **Reason for being discharged**    |         |      |
| Discharged after healthy certification | 539  | 92   |
| +DAMA                              | 10      | 1.7  |
| Death                              | 30      | 5.1  |
| Referred to another centre         | 7       | 1.2  |

* i.e. Congestive Cardiac Failure (CCF), pneumonia, chronic ulcer, uterine fibroid, cancer, TB; +Discharge Against Medical Advise (DAMA)
Table 2: probability of patients’ clinical recovery from COVID-19 at different time point

| Time (in days) | Probability of recovery | Standard error |
|---------------|-------------------------|----------------|
| 5             | 0.0172                  | 0.0054         |
| 10            | 0.0814                  | 0.0114         |
| 15            | 0.3382                  | 0.0199         |
| 20            | 0.4592                  | 0.0211         |
| 25            | 0.9068                  | 0.0127         |

Table 3: median duration of recovery from COVID-19 with respect to the covariates for patients attended at the treatment centres in Ekiti State

| Variables                        | Median (in days) | 95%CI     | Log-rank value | P-value |
|----------------------------------|------------------|-----------|----------------|---------|
| Sex                              |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 4.03           | 0.0447* |
| Male                             | 21               | 20.46-21.54 |               |         |
| Female                           | 20               | 18.27-21.74 |               |         |
| Age (years)                      |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 11.7           | 0.0085* |
| <24                              | 16               | 12.76-19.24 |               |         |
| 25-44                            | 21               | 20.14-21.86 |               |         |
| 45-64                            | 22               | 21.41-22.59 |               |         |
| ≥65                              | 22               | 20.63-23.38 |               |         |
| Admission status                 |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 17.71          | 0.000*  |
| Admitted                         | 18               | 16.39-19.61 |               |         |
| Not admitted                     | 23               | 22.74-23.26 |               |         |
| Symptoms on admission            |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 6.36           | 0.0117* |
| Absent                           | 22               | 21.63-22.37 |               |         |
| Present                          | 15               | 13.26-16.74 |               |         |
| Oxygen therapy                   |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 0.019          | 0.8897  |
| No                               | 21               | 20.58-21.42 |               |         |
| Yes                              | 17               | 14.52-19.48 |               |         |
| Presence of co-morbidity         |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 15.79          | 0.0001* |
| No                               | 21               | 19.91-22.10 |               |         |
| Yes                              | 22               | 21.16-22.84 |               |         |
| Co-morbidity condition           |                  |           |                |         |
| Overall                          | 21               | 20.46-21.54 | 19.47          | 0.0006* |
| No condition                     | 21               | 20.18-21.82 |               |         |
| Hypertension                     | 21               | 20.11-21.89 |               |         |
| Diabetes                         | 23               | 17.65-28.35 |               |         |
| Hypertension and diabetes        | 22               | 20.36-23.64 |               |         |
| Others i.e. CCF, pneumonia, chronic ulcer, uterine fibroid, cancer, TB | 23 | 19.88-26.12 |         |

* i.e. CCF, pneumonia, chronic ulcer, uterine fibroid, cancer, TB
Table 4: multivariable cox regression analysis of time to recovery and its predictors among patients attended at the treatment centres in Ekiti State

| Variables                              | HR   | 95%CI     | P-value | aHR   | 95%CI     | P-value |
|----------------------------------------|------|-----------|---------|-------|-----------|---------|
| Sex                                    |      |           |         |       |           |         |
| Male (ref)                             | 1    |           |         |       |           |         |
| Female                                 | 1.16 | 0.98-1.36 | 0.077   |       |           |         |
| Age (years)                            |      |           |         |       |           |         |
| <24 (ref)                              | 1    |           |         |       |           |         |
| 25-44                                  | 0.98 | 0.75-1.29 | 0.902   | 0.91  | 0.69-1.20 | 0.565   |
| 45-64                                  | 0.81 | 0.60-1.09 | 0.16    | 0.86  | 0.63-1.17 | 0.565   |
| ≥65                                    | 0.89 | 0.64-1.23 | 0.472   | 0.87  | 0.58-1.32 | 0.565   |
| Admission status                       |      |           |         |       |           |         |
| Admitted (ref)                         | 1    |           |         |       |           |         |
| Not admitted                           | 0.75 | 0.63-0.88 | 0.001*  | 0.71  | 0.56-0.88 | 0.002*  |
| Symptoms on admission                  |      |           |         |       |           |         |
| Absent (ref)                           | 1    |           |         |       |           |         |
| Present                                | 0.75 | 0.63-0.88 | 0.001*  | 0.81  | 0.66-0.99*| 0.02*   |
| Oxygen therapy                         |      |           |         |       |           |         |
| No (ref)                               | 1    |           |         |       |           |         |
| Yes                                    | 1.47 | 1.17-1.85 | 0.001*  | 0.82  | 0.60-1.12 | 0.2     |
| Presence of co-morbidity               |      |           |         |       |           |         |
| No (ref)                               | 1    |           |         |       |           |         |
| Yes                                    | 0.69 | 0.56-0.85 | 0.000*  | 1.83  | 0.72-4.60 |         |
| Co-morbidity condition                 |      |           |         |       |           |         |
| No condition (ref)                     | 1    |           |         |       |           |         |
| Hypertension                           | 0.9  | 0.68-1.17 | 0.428   | 1.56  | 0.63-3.86 | 0.33    |
| Diabetes                               | 0.52 | 0.27-1.01 | 0.052   | 0.78  | 0.25-2.43 | 0.671   |
| Hypertension and diabetes              | 0.62 | 0.44-0.87 | 0.006*  | 0.99  | 0.37-2.65 | 0.952   |
| Others i.e. CCF, pneumonia, chronic ulcer, uterine fibroid, cancer, TB | 0.58 | 0.36-0.92 | 0.021*  | 0.82  | 0.29-2.29 | 0.834   |

*statistically significant
**Figure 1**: Kaplan-Meier recovery curve of COVID-19 patient with respect to the covariates